Tags

Type your tag names separated by a space and hit enter

Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.
J Ovarian Res. 2014 Mar 14; 7:31.JO

Abstract

BACKGROUND

Women with polycystic ovary syndrome (PCOS) have higher risk for cardiovascular disease (CVD). Copeptin has been found to be predictive for myocardial ischemia. We tested whether copeptin is the predictor for CVD in PCOS patients, who have an increased risk of cardiovascular disease.

METHODS

This was a cross sectional controlled study conducted in a training and research hospital. The study population consisted of 40 reproductive-age PCOS women and 43 control subjects. We evaluated anthropometric and metabolic parameters, carotid intima media thickness and copeptin levels in both PCOS patients and control group.

RESULTS

Mean fasting insulin, homeostasis model assessment insulin resistance index (HOMA-IR), triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), free testosterone, 17-OH progesterone, Dehydroepiandrosterone sulfate (DHEAS), carotid intima media thickness (CIMT) levels were significantly higher in PCOS patients. Mean copeptin level was in 12.61 ± 3.05 pmol/L in PCOS patients while mean copeptin level was 9.60 ± 2.80 pmol/L in healthy control women (p < 0.001). After adjustment for age and BMI, copeptin level was positive correlated with fasting insulin, free testosterone levels, CIMT, and HOM A-IR.

CONCLUSIONS

Copeptin appeared to have an important role in metabolic response and subsequent development of atherosclerosis in insulin resistant, hyperandrogenemic PCOS patients.

Links

PMC Free PDF

Authors+Show Affiliations

Karbek B
Department of Endocrinology and Metabolic Diseases, Gaziantep Dr, Ersin Arslan Hospital, Milli Egemenlik bulvarı, Sanlılar Apt, no:51 daire:9 Şehitkamil/Gaziantep, Gaziantep, Turkey. b_karbek@yahoo.com.
Ozbek M
No affiliation info available
Karakose M
No affiliation info available
Topaloglu O
No affiliation info available
Bozkurt NC
No affiliation info available
Cakır E
No affiliation info available
Aslan MS
No affiliation info available
Delibasi T
No affiliation info available

MeSH

AdolescentAdultBiomarkersBlood GlucoseCarotid Artery DiseasesCarotid Intima-Media ThicknessCase-Control StudiesCross-Sectional StudiesFemaleGlycopeptidesHormonesHospitals, TeachingHumansHyperandrogenismInsulinInsulin ResistanceLipidsPolycystic Ovary SyndromePredictive Value of TestsPrognosisRisk FactorsTurkeyYoung Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24628831

Citation

Karbek, Basak, et al. "Copeptin, a Surrogate Marker for Arginine Vasopressin, Is Associated With Cardiovascular Risk in Patients With Polycystic Ovary Syndrome." Journal of Ovarian Research, vol. 7, 2014, p. 31.
Karbek B, Ozbek M, Karakose M, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res. 2014;7:31.
Karbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N. C., Cakır, E., Aslan, M. S., & Delibasi, T. (2014). Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. Journal of Ovarian Research, 7, 31. https://doi.org/10.1186/1757-2215-7-31
Karbek B, et al. Copeptin, a Surrogate Marker for Arginine Vasopressin, Is Associated With Cardiovascular Risk in Patients With Polycystic Ovary Syndrome. J Ovarian Res. 2014 Mar 14;7:31. PubMed PMID: 24628831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. AU - Karbek,Basak, AU - Ozbek,Mustafa, AU - Karakose,Melia, AU - Topaloglu,Oya, AU - Bozkurt,Nujen Colak, AU - Cakır,Evrim, AU - Aslan,Muyesser Sayki, AU - Delibasi,Tuncay, Y1 - 2014/03/14/ PY - 2013/10/12/received PY - 2014/02/11/accepted PY - 2014/3/18/entrez PY - 2014/3/19/pubmed PY - 2014/3/19/medline SP - 31 EP - 31 JF - Journal of ovarian research JO - J Ovarian Res VL - 7 N2 - BACKGROUND: Women with polycystic ovary syndrome (PCOS) have higher risk for cardiovascular disease (CVD). Copeptin has been found to be predictive for myocardial ischemia. We tested whether copeptin is the predictor for CVD in PCOS patients, who have an increased risk of cardiovascular disease. METHODS: This was a cross sectional controlled study conducted in a training and research hospital. The study population consisted of 40 reproductive-age PCOS women and 43 control subjects. We evaluated anthropometric and metabolic parameters, carotid intima media thickness and copeptin levels in both PCOS patients and control group. RESULTS: Mean fasting insulin, homeostasis model assessment insulin resistance index (HOMA-IR), triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), free testosterone, 17-OH progesterone, Dehydroepiandrosterone sulfate (DHEAS), carotid intima media thickness (CIMT) levels were significantly higher in PCOS patients. Mean copeptin level was in 12.61 ± 3.05 pmol/L in PCOS patients while mean copeptin level was 9.60 ± 2.80 pmol/L in healthy control women (p < 0.001). After adjustment for age and BMI, copeptin level was positive correlated with fasting insulin, free testosterone levels, CIMT, and HOM A-IR. CONCLUSIONS: Copeptin appeared to have an important role in metabolic response and subsequent development of atherosclerosis in insulin resistant, hyperandrogenemic PCOS patients. SN - 1757-2215 UR - https://www.unboundmedicine.com/medline/citation/24628831/Copeptin_a_surrogate_marker_for_arginine_vasopressin_is_associated_with_cardiovascular_risk_in_patients_with_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -